Evidence map›Paper›PMID 35572573›Full record

ArticleFrontiers in immunology2022

Early Post-Vaccination Gene Signatures Correlate With the Magnitude and Function of Vaccine-Induced HIV Envelope-Specific Plasma Antibodies in Infant Rhesus Macaques.

K K Vidya Vijayan, Kaitlyn A Cross, Alan D Curtis, Koen K A Van Rompay, Justin Pollara, Christopher B Fox, Mark Tomai, Tomáš Hanke, Genevieve Fouda, Michael G Hudgens and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. The Many Hosts of Mycobacteria 9 (MHM9): A conference report.Tuberculosis (Edinburgh, Scotland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

K K Vidya VijayanDepartment of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Kaitlyn A CrossDepartment of Biostatistics, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Alan D CurtisDepartment of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Koen K A Van RompayCalifornia National Primate Research Center, University of California, Davis, Davis, CA, United States.
Justin PollaraDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States.
Christopher B FoxInfectious Disease Research Institute, Seattle, WA, United States.
Mark Tomai3M Corporate Research Materials Laboratory, Saint Paul, MN, United States.
Tomáš HankeThe Jenner Institute, University of Oxford, Oxford, United Kingdom.
Genevieve FoudaDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States.
Michael G HudgensDepartment of Biostatistics, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Sallie R PermarDepartment of Pediatrics, Weill Cornell Medical College, New York, NY, United States.
Kristina De ParisDepartment of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
University of North Carolina at Chapel Hill · USCornell University · USDuke Medical Center · USDuke University · USInfectious Disease Research Institute · USUniversity of California, Davis · USUniversity of Oxford · GB

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Project 2: RNA vaccination in early life to induce potent and broad HIV Env-specific antibody responsesP01AI117915 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE PARIS, KRISTINA, PERMAR, SALLIE R. · 2015 to 2024
$21.2M
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in InfantsR01DE028146 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DE PARIS, KRISTINA · 2018 to 2022
$4.6M
Viral Pathogenesis Training ProgramT32AI083203 · NIAID · UNIVERSITY OF WASHINGTON · PI BLOOM, JESSE D, LAGUNOFF, MICHAEL · 2009 to 2023
$2.7M
Medical Research Council MR/N023668/1NCI NIH HHS P30 CA016086NIAID NIH HHS P01 AI117915NIAID NIH HHS P30 AI050410NIAID NIH HHS T32 AI083203NIDCR NIH HHS R01 DE028146NIH HHS P51 OD011107
6 · The paper itself

Abstract

A better understanding of the impact of early innate immune responses after vaccine priming on vaccine-elicited adaptive immune responses could inform rational design for effective HIV vaccines. The current study compared the whole blood molecular immune signatures of a 3M-052-SE adjuvanted HIV Env protein vaccine to a regimen combining the adjuvanted Env protein with simultaneous administration of a modified Vaccinia Ankara vector expressing HIV Env in infant rhesus macaques at days 0, 1, and 3 post vaccine prime. Both vaccines induced a rapid innate response, evident by elevated inflammatory plasma cytokines and altered gene expression. We identified 25 differentially-expressed genes (DEG) on day 1 compared to day 0 in the HIV protein vaccine group. In contrast, in the group that received both the Env protein and the MVA-Env vaccine only two DEG were identified, implying that the MVA-Env modified the innate response to the adjuvanted protein vaccine. By day 3, only three DEG maintained altered expression, indicative of the transient nature of the innate response. The DEG represented immune pathways associated with complement activation, type I interferon and interleukin signaling, pathogen sensing, and induction of adaptive immunity. DEG expression on day 1 was correlated to Env-specific antibody responses, in particular antibody-dependent cytotoxicity responses at week 34, and Env-specific follicular T helper cells. Results from network analysis supported the interaction of DEG and their proteins in B cell activation. These results emphasize that vaccine-induced HIV-specific antibody responses can be optimized through the modulation of the innate response to the vaccine prime.

Indexed as

AIDS VaccinesHIV InfectionsAdjuvants, ImmunologicAnimalsGene Products, envHIV AntibodiesHumansMacaca mulattaVaccinationVaccinia virusViral Envelope ProteinsAdjuvants, ImmunologicAIDS VaccinesGene Products, envHIV AntibodiesViral Envelope Proteinsearly life HIV vaccineinnate gene signaturesrhesus macaque modelsystems biologyvaccine-induced antibody response

Identifiers

PMID35572573
PMCPMC9094446
OpenAlexW4224936619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.